Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary
embolism (PE), presents a large clinical burden. Prompt, effective and sustained …

Rivaroxaban (Xarelto®), a direct factor Xa inhibitor, is approved for the prevention of stroke
and systemic embolism in patients with atrial fibrillation (AF) in Canada or those with …

Endovenous recanalization with percutaneous transluminal angioplasty and stenting in post-
thrombotic syndrome patients with iliocaval obstruction is a treatment modality quickly …

Introduction: A pro-coagulant state during pregnancy can be involved in the occurrence of
gestational vascular complications (GVCs) and venous thromboembolism (VTE). Areas …

The purpose of this European Heart Rhythm Association (EHRA) survey was to assess
clinical practice in relation to stroke prevention in atrial fibrillation (AF), particularly into the …

Rivaroxaban is the first agent available within a new class of anticoagulants called direct
factor X a inhibitors. Rivaroxaban is approved for use in the U nited S tates for the prevention …

Oral anticoagulant therapy, either with vitamin K antagonists (VKAs) or with novel oral
anticoagulants such as dabigatran, rivaroxaban, and apixaban, is the mainstay for …

Dabigatran etexilate (DE), rivaroxaban, and apixaban are nonvitamin K antagonist oral
anticoagulants (NOACs) that have been compared in clinical trials with existing …

Venous thromboembolism is a preventable medical condition associated with significant
morbidity and mortality. It can lead to deep vein thrombosis, pulmonary embolism, and …

O manuseio peri-operatório do doente medicado cronicamente com anticoagulantes e
antiagregantes plaquetários, comum na prática clínica, não deixa de ser um problema …